Amplifyer Bio's lead program aims to impact the key challenges of using liquid biopsies as cancer diagnostics by preventing circulating tumor DNA (ctDNA) nuclease degradation and cellular uptake, thus improving clinical sensitivity. The priming agent incorporates into current clinical protocols, reducing cost and burden to patients.
